Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States
Rimegepant initiation was associated with reductions in utilization of opioids and butalbital, including in individuals using preventive treatment for migraine, and with reduction of opioid utilization in individuals with problematic opioid use.
Authors
- Josh Brown
- Karin Hygge Blakeman (ORCID: https://orcid.org/0000-0001-6925-7099)
- Lucy Abraham (ORCID: https://orcid.org/0000-0003-1648-8621)
- Noah Rosen (ORCID: https://orcid.org/0000-0002-5657-2206)
- Aaron Jenkins (ORCID: https://orcid.org/0000-0001-9785-9388)
- Feng Dai (ORCID: https://orcid.org/0000-0002-9963-6863)
- Chelsea Leroue
Institutions
- Northwell Health (US)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (Sweden) (SE)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1111/head.15004
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Pfizer